» Articles » PMID: 33193429

The Oral Microbiome and Cancer

Overview
Journal Front Immunol
Date 2020 Nov 16
PMID 33193429
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

There is mounting evidence that members of the human microbiome are highly associated with a wide variety of cancer types. Among oral cancers, oral squamous cell carcinoma (OSCC) is the most prevalent and most commonly studied, and it is the most common malignancy of the head and neck worldwide. However, there is a void regarding the role that the oral microbiome may play in OSCC. Previous studies have not consistently found a characteristic oral microbiome composition associated with OSCC. Although a direct causality has not been proven, individual members of the oral microbiome are capable of promoting various tumorigenic functions related to cancer development. Two prominent oral pathogens, , and can promote tumor progression in mice. infection has been associated with oro-digestive cancer, increased oral cancer invasion, and proliferation of oral cancer stem cells. The microbiome can influence the evolution of the disease by directly interacting with the human body and significantly altering the response and toxicity to various forms of cancer therapy. Recent studies have shown an association of certain phylogenetic groups with the immunotherapy treatment outcomes of certain tumors. On the other side of the coin, recently it has been a resurgence in interest on the potential use of bacteria to cure cancer. These kinds of treatments were used in the late nineteenth and early twentieth centuries as the first line of defense against cancer in some hospitals but later displaced by other types of treatments such as radiotherapy. Currently, organisms such as and spp. have been used for targeted strategies as potential vectors to treat cancer. In this review, we briefly summarize our current knowledge of the role of the oral microbiome, focusing on its bacterial fraction, in cancer in general and in OSCC more precisely, and a brief description of the potential use of bacteria to target tumors.

Citing Articles

Exploring the role of oral bacteria in oral cancer: a narrative review.

Mivehchi H, Eskandari-Yaghbastlo A, Pour Bahrami P, Elhami A, Faghihinia F, Nejati S Discov Oncol. 2025; 16(1):242.

PMID: 40009328 PMC: 11865422. DOI: 10.1007/s12672-025-01998-2.


Immunomodulatory effects of Triphala and its constituents in oral squamous cell carcinoma and oral precancer.

Dineshkumar T, Anandan N, Rajkumar K, Nandhakumar I J Oral Maxillofac Pathol. 2025; 28(4):657-664.

PMID: 39949672 PMC: 11819626. DOI: 10.4103/jomfp.jomfp_53_24.


Human papillomavirus, vaginal microbiota and metagenomics: the interplay between development and progression of cervical cancer.

Leon-Gomez P, Romero V Front Microbiol. 2025; 15:1515258.

PMID: 39911706 PMC: 11794528. DOI: 10.3389/fmicb.2024.1515258.


Oral microbiota: the overlooked catalyst in cancer initiation and progression.

Wang X, He X, Zhong B Front Cell Dev Biol. 2025; 12:1479720.

PMID: 39872848 PMC: 11769975. DOI: 10.3389/fcell.2024.1479720.


Oral Pathogens' Substantial Burden on Cancer, Cardiovascular Diseases, Alzheimer's, Diabetes, and Other Systemic Diseases: A Public Health Crisis-A Comprehensive Review.

Murray P, Coffman J, Garcia-Godoy F Pathogens. 2025; 13(12.

PMID: 39770344 PMC: 11677847. DOI: 10.3390/pathogens13121084.


References
1.
Tateda M, Shiga K, Saijo S, Sone M, Hori T, Yokoyama J . Streptococcus anginosus in head and neck squamous cell carcinoma: implication in carcinogenesis. Int J Mol Med. 2000; 6(6):699-703. DOI: 10.3892/ijmm.6.6.699. View

2.
Binder Gallimidi A, Fischman S, Revach B, Bulvik R, Maliutina A, Rubinstein A . Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget. 2015; 6(26):22613-23. PMC: 4673186. DOI: 10.18632/oncotarget.4209. View

3.
Rubinstein M, Baik J, Lagana S, Han R, Raab W, Sahoo D . promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep. 2019; 20(4). PMC: 6446206. DOI: 10.15252/embr.201847638. View

4.
Del Castillo E, Meier R, Chung M, Koestler D, Chen T, Paster B . The Microbiomes of Pancreatic and Duodenum Tissue Overlap and Are Highly Subject Specific but Differ between Pancreatic Cancer and Noncancer Subjects. Cancer Epidemiol Biomarkers Prev. 2018; 28(2):370-383. PMC: 6363867. DOI: 10.1158/1055-9965.EPI-18-0542. View

5.
Ochi A, Nguyen A, Bedrosian A, Mushlin H, Zarbakhsh S, Barilla R . MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med. 2012; 209(9):1671-87. PMC: 3428946. DOI: 10.1084/jem.20111706. View